Vital Signs - Molecular Diagnostics Market Review: Opportunities in Infectious Diseases, Oncology, Carrier Screening, and Prenatal Testing

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on July 6, 2011, provides a strategic insight on the molecular diagnostics market.

Additionally, a company spotlight is provided for Stratos Genomics, a company that is developing a next generation DNA sequencing technology that enables accurate and ultra-low cost whole genome sequencing non-invasive imaging system that provides automated ultrasound images of the human breast. Reimbursement and regulatory news from the FDA is also provided for week of Jun 6, 2011.

Table of Contents

Vital Signs - Molecular Diagnostics Market Review: Opportunities in Infectious Diseases, Oncology, Carrier Screening, and Prenatal TestingVital Signs: 6 July 2011This week's issue




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Release Date : 31-Oct-17

Region : North America

Release Date : 30-Oct-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.